Thoracic Neoplasm

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

The expression of PIM1, p-STAT3, and c-MYC was tested (IHC) in 194 NSCLC archival tumor samples. High nuclear expression of PIM1 was detected in 43.3% of cases and was significantly correlated with ad… (full text at CIViC)

PMID 26918046 · Jiang et al., 2016 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mut… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous muta… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious Y956N mutation (as determined by Polyphen or SIFT), treated with pembrolizumab … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLE4 deleterious A59E mutation (as determined by Polyphen or SIFT), treated with pembrolizumab m… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective analysis of the Hellmann cohort of 75 patients with non-small cell lung cancer treated with combined PD-1 and CTLA-4 blockade, 6 patients with nonsynonymous PRKDC mutations had a hi… (full text at CIViC)

PMID 32502294 · Chen et al., 2020 · Open in CIViC

PTPRF expression was found to be prognostic for shorter overall survival but was also significantly predictive of improved survival with erlotinib versus placebo in SATURN even in the EGFR wild-type … (full text at CIViC)

PMID 26291013 · Soulières et al., 2015 · Open in CIViC

PTPRF expression was found to be prognostic for shorter overall survival but was also significantly predictive of improved survival with erlotinib versus placebo in SATURN even in the EGFR wild-type s… (full text at CIViC)

PMID 26291013 · Soulières et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PXDNL deleterious P1460T mutation, treated with pembrolizumab monotherapy, was associated with a … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

Approximately 2% of NSCLCs had RASA1 truncating mutations, and this alteration was statistically, but not completely, mutually exclusive with known activating EGFR (p=0.02) and KRAS (p=0.02) mutations… (full text at CIViC)

PMID 29127119 · Hayashi et al., 2018 · Open in CIViC

Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study. This finding was independent from othe… (full text at CIViC)

PMID 22619677 · Zhao et al., 2012 · Open in CIViC

Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds rat… (full text at CIViC)

PMID 26802149 · Dowlati et al., 2016 · Open in CIViC

A phase II clinical study was conducted with 29 patients with Non-Small-Cell Lung Cancer harboring CDKN2A alterations and wild-type Rb. The study reported one patient with a partial response, and six … (full text at CIViC)

PMID 35050752 · Ahn et al., 2020 · Open in CIViC

ASCL1 and RET mRNA levels were examined by microarray analysis in lung cancer samples. High expression of RET (RET-high) correlated with shorter overall survival compared to the RET-low group in patie… (full text at CIViC)

PMID 24037524 · Kosari et al., 2014 · Open in CIViC

Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alterat… (full text at CIViC)

PMID 26370156 · Cheng et al., 2015 · Open in CIViC

In a phase 2 basket trial, patients with small-cell lung carcinoma (SLC) who failed platinum-based chemotherapy and harbored RICTOR amplification were treated with mTOR 1/2 inhibitor vistusertib (AZD2… (full text at CIViC)

Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 A77P was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 A… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 A77S was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 A… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 F82L was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 F… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 M90I was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 M… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in approx. 2% of lung adenocarcinomas (5/87 in the "oncogene negative" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation). GD… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

This study contained 230 patients with untreated lung adenocarcinoma. Whole-exome sequencing of tumor cells yielded that RTK/RAS/RAF based mutations to be 62%. However, analysis shows that NF1 mutatio… (full text at CIViC)

PMID 25079552 · 2014, Nature · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 Q40L was expressed in NIH3T3 cells and did not induce colony formation in soft agar greater tha… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 Q79L, a known activating mutation, was expressed in NIH3T3 cells and induced colony formation i… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

A patient with ROS1 fusion-positive NSCLC was treated with crizotinib for 26 months led to response (-64%). After tumor progression, a rebiopsy sample was obtained and revealed ROS1 D2033N mutation. S… (full text at CIViC)

PMID 26673800 · Drilon et al., 2016 · Open in CIViC

In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC)

PMID 29333528 · Gainor et al., 2017 · Open in CIViC

In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC)

PMID 29333528 · Gainor et al., 2017 · Open in CIViC

Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistan… (full text at CIViC)

PMID 23724914 · Awad et al., 2013 · Open in CIViC

Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival o… (full text at CIViC)

PMID 25351743 · Katayama et al., 2015 · Open in CIViC

Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. An acquired G2032R mut… (full text at CIViC)

PMID 23724914 · Awad et al., 2013 · Open in CIViC

In preclinical models, DS-6051b inhibited tumour growth and phospho-ROS1 levels in CD74-ROS1 G2032R mutant Ba/F3 cells. Similar results were seen in the crizotinib-resistant patient derived MGH047-4 c… (full text at CIViC)

PMID 31399568 · Katayama et al., 2019 · Open in CIViC

Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M muta… (full text at CIViC)

PMID 25733882 · Zou et al., 2015 · Open in CIViC

In a phase 1-2 trial (NCT03093116), the ROS1/ALK/NTRK inhibitor repotrectinib demonstrated efficacy in NSCLC with ROS1 fusions. In the 56 patients who had previously received one ROS1 tyrosine kinase… (full text at CIViC)

PMID 38197815 · Drilon et al., 2024 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib.

PMID 25688157 · Song et al., 2015 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib.

PMID 25688157 · Song et al., 2015 · Open in CIViC

Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cel… (full text at CIViC)

PMID 25733882 · Zou et al., 2015 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74–ROS1; however, showed similar sensitivity t… (full text at CIViC)

PMID 25688157 · Song et al., 2015 · Open in CIViC